A recent study reported the detection of a bat-derived virus (BatPV/Epo_spe/AR1/DCR/2009, batMuV) with phylogenetic relatedness to human mumps virus (hMuV). Since all efforts to isolate infectious batMuV have reportedly failed, we generated recombinant mumps viruses (rMuVs) in which the open reading frames (ORFs) of the fusion (F) and haemagglutinin-neuraminidase (HN) glycoproteins of an hMuV strain were replaced by the corresponding ORFs of batMuV. The batMuV F and HN proteins were successfully incorporated into viral particles and the resultant chimeric virus was able to mediate infection of Vero cells. Distinct differences were observed between the fusogenicity of rMuVs expressing one or both batMuV glycoproteins: viruses expressing batMuV F were highly fusogenic, regardless of the origin of HN. In contrast, rMuVs expressing human F and bat-derived HN proteins were less fusogenic compared to hMuV. The growth kinetics of chimeric MuVs expressing batMuV HN in combination with either hMuV or batMuV F were similar to that of the backbone virus, whereas a delay in virus replication was obtained for rMuVs harbouring batMuV F and hMuV HN. Replacement of the hMuV F and HN genes or the HN gene alone by the corresponding batMuV genes led to a slight reduction in neurovirulence of the highly neurovirulent backbone strain. Neutralizing antibodies inhibited infection mediated by all recombinant viruses generated. Furthermore, group IV anti-MuV antibodies inhibited the neuraminidase activity of bat-derived HN. Our study reports the successful generation of chimeric MuVs expressing the F and HN proteins of batMuV, providing a means for further examination of this novel batMuV.
INTRODUCTION
Mumps virus (MuV) is a member of the genus Rubulavirus within the family Paramyxoviridae. The non-segmented negative-stranded RNA genome has a size of 15 384 nt and contains open reading frames (ORFs) for seven structural viral proteins from the 3¢ to the 5¢ terminus: the nucleoprotein (N), matrix protein (M), phosphoprotein (P), fusion protein (F), small hydrophobic protein (SH), haemagglutinin-neuraminidase protein (HN) and RNA-dependent RNA polymerase protein (L) (Elango et al., 1988) . Each gene, with the exception of that which encodes the P gene, encodes for a single viral protein. The gene that encodes the P protein also encodes the V protein and the putative I protein. The V protein is produced from a faithful transcript of the gene, whereas post-transcriptional editing gives rise to mRNAs encoding the P and I proteins (Paterson et al., 1990) .
Mumps is a highly contagious disease caused by MuV. The hallmark of MuV infection is parotitis (CDC, 2015) ; however, mumps can lead to more significant complications such as orchitis, encephalitis or meningitis (Beard et al., 1977; Russell et al., 1958) . virus (batMuV) is similar to that of human MuV (hMuV). Furthermore, the genome of batMuV is of polyhexameric length (a multiple of six), which is common to all members of the Paramyxoviridae, probably for efficient replication (Calain & Roux, 1993; Hausmann et al., 1996 , Kolakofsky et al., 2005 . The amino acid homology between the batMuV genes and the corresponding hMuV genes is above 90 % with the exception of the SH protein, a non-essential protein known to be hypervariable in sequence (Orvell et al., 2002; Takeuchi et al., 1996) . However, to date, all efforts to isolate infectious batMuV have failed, which makes it difficult to evaluate the zoonotic potential of this bat-derived paramyxovirus.
The MuV HN protein, a type II membrane protein, binds to sialic acids of cell surface macromolecules and thereby initiates the infection of target cells (Samal, 2011) . In addition, MuV HN exhibits neuraminidase activity to release newly synthesized virions from the cellular membrane of infected cells. Neuraminidase activity varies across different MuV strains (Hosaka et al., 1998; Brostrom et al., 1971; Leprat & Aymard, 1979; Merz & Wolinsky, 1981; Santos-López et al., 2009) . In a previous study we reported that batMuV HN binds to chicken erythrocytes in a sialic acid-dependent manner and exhibits neuraminidase activity (Krüger et al., 2015) .
The F protein, a type I membrane protein, mediates the fusion of the viral envelope with the plasma membrane of target cells to release the viral genome into the cytoplasm.
Co-expression of MuV F and HN on the surface of infected cells results in the fusion of neighbouring cells and thus in the formation of multinucleated giant cells, so-called syncytia (McCarthy & Johnson, 1980; Wolinsky & Stroop, 1978) . For the batMuV glycoproteins, we have shown that coexpression of F and HN resulted in cell-to-cell fusion in different mammalian cell lines (Krüger et al., 2015) .
A recently published study described the generation of recombinant MuV (rMuV) expressing the batMuV glycoproteins in a human backbone virus (Odate strain) (Katoh et al., 2016) . In that report, it was shown that these viruses differed in both their fusogenicity and growth kinetics when compared to Odate, and that neutralizing antibodies directed against human MuV cross-neutralized chimeric MuV. However, all data were obtained from in vitro experiments lacking information on potential differences in in vivo infectivity and virulence of rMuV harbouring batMuV glycoproteins.
In this study, we report the successful generation of rMuVs in which the ORFs of the F and/or HN protein of a highly neurovirulent hMuV isolate (strain 88-1961) (Amexis et al., 2003) were replaced by the corresponding ORFs of batMuV. Besides analysing viral replication and fusogenicity, we also investigated the expression of viral glycoproteins incorporated in recombinant viruses, as well as the neurovirulence of chimeric viruses. In contrast to Katoh et al. (2016) , we demonstrate that rMuVs harbouring batMuV F are highly fusogenic, whereas the fusion activity of rMuV expressing hMuV F together with batMuV HN is low.
While most rMuVs displayed growth characteristics similar to recombinant authentic MuV 88-1961, rMuVs harbouring batMuV F and hMuV HN were delayed in virus replication and had lower peak titres. The replacement of viral glycoproteins of hMuV by the corresponding glycoproteins of batMuV did not affect virus neurovirulence in newborn rats. Antibodies directed against hMuV strains inhibited infection mediated by rMuVs expressing batMuV glycoproteins, as well as the neuraminidase activity of viruses expressing the batMuV HN.
RESULTS
Rescue and sequence analysis of rMuV Chimeric rMuV was generated employing the r88modDNhe backbone in which no ORFs (r88modDNhe, r88modDNhe +Xho), only one ORF (r88_batF, r88_batHN) or both ORFs (r88_batF+HN) of the MuV glycoproteins F and HN were replaced by their counterparts of batMuV. To enable directed cloning of chimeric cDNA plasmids, we altered the XhoI restriction site at nucleotide positions 6606-6611 by introduction of a single nucleotide substitution (r88mod-DNhe+Xho). In order to ensure that this modification had no influence on viral replication and functional activity of the viral glycoproteins, we compared all results obtained for r88modDNhe+Xho to those obtained for r88modDNhe. Also, to exclude random mutations arising during rescue and propagation of rMuV causing glycoprotein-independent changes in viral replication and functional activity of MuV F and HN glycoproteins, we rescued rMuV twice in independent preparations and fully sequenced it, except for the extreme genomic termini. Nucleotide mutations detected in the 10 viruses are listed in Table 1. No mutations were detected in three of the viruses, and in the others all but two were in the form of nucleotide heterogeneities one being a silent mutation and the other a coding change in a non-conserved region of the L gene (Sidhu et al., 1993) . An insertion of an eighth A in the F-SH UTR was also observed, which has been described recently . These seemingly random mutations did not appear to affect virus phenotype based on viral replication, fusogenicity and neurovirulence in the rat model.
BatMuV F and HN glycoproteins are incorporated into chimeric rMuV
Cells were infected with rMuV and stained for the detection of viral glycoproteins using antibodies directed against the cytoplasmic tail of MuV F or HN proteins. As shown for r88modDNhe+Xho and r88_batF+HN as representative examples, both hMuV and batMuV glycoproteins could be detected in infected cells (Fig. 1) . The same result was obtained for rMuV r88_batF and r88_batHN, which express one human glycoprotein and one bat-derived glycoprotein (data not shown). The fluorescence intensity and the expression pattern of batMuV F and HN were similar compared to the corresponding hMuV glycoproteins (Fig. 1 ).
The expression of MuV glycoproteins in virus particles was also investigated by SDS-PAGE followed by Western blotting. Purified rMuV, as well as cell culture supernatant of mock-infected cells (control), was loaded on an SDS gel and incubated with antibodies for the detection of MuV N, P, F or HN. As shown in Fig. 2(a) , specific bands for viral proteins were detected in all rMuV generated but not in the control. Furthermore, no significant differences were obtained when the relative protein contents of MuV P, F and HN of the different rMuVs generated were compared (data not shown). A strong band for MuV N was detected at the predicted molecular mass of~69 kDa (Fig. 2a) . For MuV P, a protein band of high intensity was detected at the predicted molecular height of MuV P (45 kDa). In addition, protein bands of weaker intensity were detected at approximately 35-25 kDa for all rMuV, but not in the mockinfected control (Fig. 2a) . The occurrence of multiple protein bands for MuV P, which have been identified as digestion products of MuV P, has been described by others (Cox et al., 2013) . As far as the F protein is concerned, under reducing conditions only one protein band was detected at a molecular mass of approximately 55 kDa, most likely representing the cleaved F 1 subunit of MuV F (Fig. 2a) . Under non-reducing conditions, protein bands of weak intensity were detected occurring at approximately 65 kDa, likely representing the monomeric F 0 . Protein bands detected at higher molecular masses from~130 kDa to >250 kDa likely represent multimeric forms of MuV F (Fig. 2b) . For the MuV HN, two protein bands that represent the monomeric HN proteins were detected at~75 and 80 kDa, whereas an additional band that was detected at~240 kDa most likely represents multimeric forms of HN (Fig. 2a) .
Detection of batMuV F and HN proteins in both rMuV particles and infected cells demonstrates that the genes for F and HN of the 88-1961 MuV strain can be successfully replaced by the corresponding batMuV genes and that their expression products are incorporated into chimeric virions.
In vitro growth kinetics of rMuV Viral replication was investigated by determining viral titres in Vero76 cells cultures over a 5-day time course following inoculation at a multiplicity of infection (MOI) of 0.05. As shown in Fig. 3 , all rMuVs reached maximum titre at 2-3 days pp.i. when the complete cell layer was infected, as evidenced by the detection of viral proteins in nearly all cells and -with the exception of r88_batHN -the widespread occurrence of syncytia (Fig. 4) . One-way ANOVA revealed statistical differences between the viral growth kinetics of r88_batF-1 and r88_batHN-2 (**P<0.01), r88_batF-2 and Table 1 . Nucleotide changes in rescued rMuV compared to the sequence of r88modDNhe
All viruses were sequenced from the nucleotide residue 96 to 15 311. The substitution of G6611 to A (deleted XhoI restriction site) is not mentioned in this table. fi: nucleotide or amino acid change; ND: none detected. For sites of heterogeneity, the fractions of wild-type nucleotide (given on the left side) and mutations (given on the right side) are indicated as follows: =, equal fractions; >, major wild-type nucleotide; <, major mutated nucleotide.
Virus
Nucleotide mutation detected in rescued virus Genetic location Amino acid change for all other viruses (Fig. 3 ).
Chimeric rMuV expressing the batMuV F protein is highly fusion active irrespective of the origin of the HN protein Vero76 cells were infected with rMuV at the same MOI (0.05) and screened for the formation of syncytia and the occurrence of a cytopathic effect (CPE) over a period of 5 days. Fusion activity, indicated by number and size of syncytia, as well as the extent of CPE in Vero76 cells, was similar for human rMuVs (r88modDNhe and r88modDNhe+Xho). For both viruses, small syncytia were detected in infected cells at 1 day p.i. (Fig. 4a ). During the following days, an increase in both number and size of syncytia was observed. A CPE characterized by the detachment and rounding of infected cells was clearly visible at 4 days p.i. At day 5 p.i., the CPE further increased and resulted in visible plaques that were surrounded by syncytia and single cells. Differences were obtained when the fusion activity of these viruses was compared to rMuV expressing batMuV glycoproteins. At 1 day p. i., r88_batF and r88_batF+HN induced formation of syncytia with a size similar to that of human rMuVs. At 2 days p.i., large syncytia and plaque formation could only be detected with viruses expressing the batMuV F protein. At this point, the size of syncytia already surpassed those which were induced by human rMuV at 5 days p.i. Prolonged incubation of cells led to a severe CPE with massive syncytia, vacuolization and extensive cell detachment ( Fig. 4a ). In contrast, the replacement of the 88-1961 HN with the bat HN resulted in reduced fusogenicity. No virus-induced CPE or plaque formation could be observed and syncytia induced by the infection mediated by r88_batHN were smaller in size and less frequent compared to syncytia induced by the other rMuV. In plaque assays with this virus, only small plaques were observed, which did not form until day 8 post inoculation, whereas plaques are usually detected by day 5 post inoculation with hMuV strains (data not shown).
When infected Vero76 cells were stained for the detection of intracellular viral proteins, the number of infected cells did not differ among the different rMuVs at 1 day p.i. (Fig. 4b) . Moreover, the spread of infection also did not differ for any of the viruses analysed at 2 days p.i.; the complete cell monolayer was infected with detection of viral proteins in nearly all cells. In summary, our results demonstrate that rMuV expressing the batMuV F protein is highly fusogenic regardless of the origin of the HN gene. In contrast to this, MuV encoding the hMuV F and batMuV HN proteins exhibited very low fusion activity compared to the 88-1961 strain.
Replacement of the hMuV F and HN glycoproteins with those from bats has a slight effect on neurovirulence in rats Given the close genetic and serologic relatedness of human and bat MuV, it was of interest to investigate whether recombinant MuVs expressing batMuV glycoproteins exhibited a neurovirulence phenotype similar to wild-type human MuV. While there is no validated animal model that accurately recapitulates the neuropathogenesis in humans, the extent of hydrocephalus induced by different MuV strains in rats following i.c. inoculation has been shown to correlate well with the neurotoxic potential of MuVs in humans (Rubin et al., 2000) . In this model, all three rMuVs expressing bat glycoproteins (r88_batF, r88_batHN and r88_batF+HN) exhibited high neurovirulence scores, although those for r88_batHN and r88_batF +HN tended to be slightly lower than for r88mod4Nhe +Xho and r88_batF (Table 2 , Fig. 5 ), suggesting that the batMuV HN gene confers a minor attenuating phenotype.
Nevertheless, these relatively minor differences were dwarfed when compared to the neurovirulence score displayed by recombinant vaccine virus strain Jeryl Lynn (Fig. 5) , which has been shown to be highly attenuated in the rat and has an excellent safety profile in humans. Of note, the neurovirulence score of r88mod4Nhe+Xho was indistinguishable from the score we have historically measured for the highly neurovirulent human clinical isolate 88-1961.
Antibodies directed against human MuV strains inhibit infection mediated by and neuraminidase activity of rMuVs expressing batMuV glycoproteins
MuV is serologically monotypic and the viral glycoproteins, especially the HN, are the main target of neutralizing antibodies (Kövamees et al., 1990; Orvell et al., 1997; Server et al., 1982) . To analyse whether anti-hMuV neutralizing antibodies are able to inhibit infection mediated by rMuV that expresses batMuV glycoproteins, we incubated viruses with sera from rabbits immunized with hMuVs followed by incubation of the virus/serum mixtures on Vero cells. As shown in Fig. 6(a) , the rabbit sera significantly reduced virus infectivity. The effect was MuV specific, as indicated by the lack of an effect of the sera on vesicular stomatitis virus (VSV) infectivity (data not shown).
After having shown that neutralizing antibodies are able to inhibit infection mediated by rMuV expressing batMuV glycoproteins, we then analysed whether group IV antiMuV antibodies that selectively inhibit the neuraminidase activity of MuV HN are also able to inhibit the enzymatic activity of batMuV HN. Therefore, r88modDNhe+Xho and r88_batHN -rMuVs that express either human-or batderived MuV HN proteins -were pre-incubated with antiMuV group IV antibodies 2034 and 5342 (Orvell, 1984) before the viruses were subjected to neuraminidase activity assay using 4-MUNANA substrate. Both antibodies inhibited the neuraminidase activity of human and bat-derived MuV HN significantly (Fig. 6b) . Whereas a reduced enzymatic activity of 46 % (antibody 5342) and 52 % (antibody 2024) was recorded for 88-1961 HN, the inhibitory effect for batMuV HN was higher: Antibodies 5342 and 2024 reduced neuraminidase activity to 24.7 % and 24.1 %, respectively. In contrast to this, the neuraminidase activity of H3N2 was only slightly affected by both antibodies, indicating their high specificity to inhibit MuV HN neuraminidase activity.
DISCUSSION
Detection of the batMuV RNA genome is a unique finding among recently detected bat-derived viruses, because the amino acid sequence homology between batMuV and hMuV is above 90 % in most genes and the genome organization is similar to that of hMuV, suggesting a close relatedness between bat-derived and human MuV. To date, all efforts to isolate infectious batMuV have failed, which makes it difficult to evaluate the zoonotic potential of this virus.
Here, we report the successful generation of chimeric human MuVs that express the F and/or HN glycoproteins of batMuV. These recombinants were able to replicate in Vero cells, indicating that the batMuV F and HN genes are functional in a viral context.
During the preparation of this manuscript, Katoh et al. reported the generation of rMuV expressing the batMuV glycoproteins using the MuV Odate strain as backbone virus, and provided first insights into the function of bat-derived F and HN in a viral context (Katoh et al., 2016) . Here, we sought to investigate the impact on viral virulence of replacement of the hMuV F and HN genes with those derived from bats, and to characterize these viruses in more detail.
Among paramyxoviruses, a specific interaction between F and HN is required to induce conformational changes in the F protein necessary to mediate fusion of the viral envelope with the target cell membrane, allowing for release of the viral RNA into the cytoplasm (Chang & Dutch, 2012) .
In vitro, F protein-mediated cell-to-cell fusion results in the formation of multinucleated giant cells, so-called syncytia, which accelerate the spread of the virus. The same process likely occurs in vivo. In general, fusion activity varies between different MuV strains and variants (Merz et al., 1983) .
We previously demonstrated that co-expression of batMuV F and HN in transfected cells resulted in the formation of syncytia that were markedly smaller than those induced by hMuV glycoproteins (Krüger et al., 2015) . However, in the present study using rMuVs, we found that those expressing the bat MuV F proteins (regardless of the origin of the HN protein) were highly fusogenic, whereas rMuV expressing the human MuV F together with the bat MuV HN was minimally fusogenic. Katoh et al. also reported that the fusion activity of rMuV differed from that mediated by the coexpression of viral glycoproteins following transfection, and that co-expression of MuV M did not affect the fusogenicity of batMuV F and HN in transfected cells (Katoh et al., 2016) . , r88_batF+HN and rJL were tested for their ability to induce hydrocephalus in the rat brain following neonatal i.c. inoculation. All bars represent the mean values of neurovirulence scores from two independent rescues each, except for virus rJL for which only one rescued virus (one litter; n=8) was tested and which had been analysed in the rat model in previous studies (Sauder et al., 2011) . Error bars denote standard errors of the means (SEM). Asterisks indicate statistical significance as compared to the groups of rats inoculated with wild-type virus r88modDNhe+Xho (**P<0.01; ***P<0.001; Mann-Whitney rank sum test). . Inhibition of infectivity and neuraminidase activity of rMuVs. (a) rMuVs were untreated or incubated with neutralizing antibodies directed against MuV SBL or Kilham strain prior to infection of Vero76 cells. Supernatants of infected cells were collected at 3 days p.i. and the virus titre was determined by plaque assay. Relative infectivity is given as a percentage (%). The infectivity of untreated viruses was set as 100 %. The graph shows the mean value and standard deviation of means of three independent trials. Asterisks indicate significance (***P<0.001). (b) H3N2, r88modDNhe+Xho and r88_batHN were preincubated with group IV anti-MuV antibody 2024 or 5342. Mock-treated (medium) and pre-incubated (2024 or 5342) viruses were incubated with 4-MUNANA and the emission at a wavelength of 460 nm was measured after excitation at a wavelength of 355 nm 1 h post-incubation, and is shown as normalized neuraminidase activity. Untreated trials were set as 100 %. Asterisks indicate significance (***P<0.001; NS: not significant).
Whereas protein expression levels of both batMuV F and HN in plasmid-transfected cells were lower compared to levels following transfection with the corresponding hMuV glycoproteins (Krüger et al., 2015) , using infectious viruses, no differences were seen between expression levels of human-and bat-derived F and HN proteins. This difference in protein expression levels in transfected versus infected cells is likely due to the fact that, in the context of a viral infection, the intergenic regions that flank each ORF and harbour transcription initiation and termination signals regulate gene transcription [reviewed in Gale et al. (2000) ] to achieve optimal levels, whereas transcription levels from plasmids transfected into cells are relatively unregulated.
Of note, we have shown here that proteolytic cleavage of batMuV F is as efficient as the cleavage of 88-1961 F and that the amounts of human-or bat-derived F and HN proteins incorporated into recombinant viruses were similar; therefore, the enhanced fusogenicity of batMuV F cannot be attributed to differences in the proteolytic activation of human-or bat-derived MuV F proteins or different expression levels of viral glycoproteins in virus particles. It has been reported in other publications that the fusogenicity differs among MuV strains and variants (Merz et al., 1983) and that single mutations in the MuV F protein may influence fusogenicity (Malik et al., 2007a (Malik et al., , 2007b Tanabayashi et al., 1993; Yoshida & Nakayama, 2010) . To date, the mechanism that underlies the differences obtained for the fusogenicity of MuV showing single nucleotide mutations is not known, but it is proposed that amino acid changes may alter the interaction between F and HN by influencing the tertiary structure (Tanabayashi et al., 1993) . It has further been shown for other paramyxoviruses that single mutations can lead to the loss or introduction of glycosylation sites that may result in decreased fusogenicity (Aguilar et al., 2006; Bagai & Lamb, 1995; McGinnes et al., 2001; von Messling & Cattaneo, 2003; Zimmer et al., 2001 ).
The reduced fusion activity of chimeric viruses expressing human F and bat-derived HN proteins compared to the authentic human MuV may be a consequence of heterologous protein expression leading to a less efficient F-HN interaction and thereby reduced activation of the fusogenic form of 88-1961 F.
Chimeric rMuV expressing batMuV HN together with either 88-1961 or batMuV F showed growth kinetics similar to the backbone virus. rMuV expressing the batMuV F protein together with the hMuV HN showed a delay in replication and a lower viral titre at 1 day p.i. At later time points, the viral titres of rMuV expressing batMuV F increased; however, the peak titre was still lower compared to that of the other rMuVs.
The high efficiency of rMuV expressing batMuV F and HN for viral replication may be a consequence of the specieshomogenous expression of the batMuV glycoproteins, which would likely enable the most efficient F-HN interaction and thereby the most effective F protein activation for fusion of viral envelope and cellular membranes of target cells. rMuVs that expressed bat-derived F and human HN proteins showed a decrease in viral replication that may be attributed to the heterologous expression of the viral glycoproteins. The similar growth kinetics of rMuVs expressing 88-1961 F with human-or bat-derived HN may be the result of F-HN interactions with similar efficiency to induce the conformational changes of the 88-1961 F protein required to enable the fusogenic form.
Taken together, our results obtained from viral growth kinetics and fusion activity point towards different replication strategies for the chimeric rMuV generated. For r88_batF, the spread of infection within the first few days is more likely mediated by cell-to-cell fusion rather than by the release of large quantities of infectious virions. In contrast to this, r88_batHN, which exhibits only a weak cell-tocell fusion activity but a rapid increase in virus titre at 1 day p.i., seems to follow a strategy where the release of high numbers of infectious virions into the environment is the main driver of virus spread. Chimeric rMuV expressing both batMuV glycoproteins may reflect a phenotype that which is similar to parental batMuV.
With regard to our assessment of neurovirulence, we demonstrate that the neurovirulence of hMuV is relatively unaffected by replacement of its F and HN glycoproteins with those derived from the bat virus. Although we measured a statistically significant difference between some of the chimeric viruses and wild-type virus, the differences were small and unlikely to be clinically meaningful. Of note, as shown previously, combined replacement of the 88-1961 F and HN genes with corresponding genes of the highly attenuated Jeryl Lynn vaccine strain led to a much more pronounced reduction in neurovirulence of the chimeric virus as compared to the minimal effect observed here with the bat F and HN genes (neurovirulence score of 7.7 for swapping of Jeryl Lynn genes versus a score of 15.6 for swapping of bat genes) (Sauder et al., 2011) . However, we are cautious not to over-interpret these data given our previous findings that hMuV neurovirulence is a multigenic trait involving genes in addition to the F and HN (Sauder et al., 2011) . Ultimately, the complete batMuV will need to be synthesized, rescued and tested to determine its potential to replicate in human cells and cause disease.
Mumps viruses are serologically monotypic, although antigenic differences between strains do affect their relative sensitivity to neutralization by heterologous strains (Rubin & Beeler, 2013) . Studies have shown that (i) bat sera detected MuV proteins in infected cells (Drexler et al., 2012) ; (ii) antibodies directed against human MuV detected batMuV glycoproteins in transfected cells (Krüger et al., 2015) ; and (iii) human sera containing neutralizing anti-MuV antibodies neutralized rMuV expressing batMuV glycoproteins (Katoh et al., 2016) . Not surprisingly, in the present study, we also show that sera from hMuV-immunized rabbits can neutralize rMuVs expressing batMuV glycoproteins. These findings clearly indicate a strong serological relatedness between batMuV and human MuV. Furthermore, antibodies that inhibit the neuraminidase activity of MuV HN can also reduce the enzymatic activity of batMuV HN. Taken together, antibodies directed against MuV are able to inhibit both entry and release of chimeric MuV expressing batMuV F and HN. Therefore, the presence of neutralizing antibodies directed against human MuV strains -obtained by either natural infection or vaccination -would likely protect from clinical infections mediated by batMuV, should batMuV be a human pathogen.
Our study investigated the functionality of batMuV F and HN glycoproteins in the viral context, as well as their contribution to neurovirulence in rats and neutralization by antibodies directed against human MuV strains. Although studies to date have failed to identify evidence of virus properties that would restrict the ability of batMuV to infect humans, those studies considered only the two genes that mediate virus attachment and entry. There are seven other virus gene products yet to be evaluated, including the nucleoprotein, phosphoprotein and large (polymerase) protein responsible for virus replication, transcription and evasion of host antiviral responses. It is therefore necessary to generate an authentic recombinant batMuV to evaluate the inter-species functional equivalence of these viruses in the context of zoonosis and virulence. At present, discussion of the potential for batMuV as a human pathogen is premature.
METHODS
Cells. BSR-T7/5 cells (Buchholz et al., 1999) , kindly provided by K. Conzelmann, were maintained in Dulbecco¢s minimum essential medium (DMEM; Gibco) supplemented with 10 % FCS (SigmaAldrich) and 1 mg ml À1 geneticin (G418; Gibco). Vero76 cells, kindly provided by A. Maisner, were maintained in DMEM supplemented with 5 % FCS. Cells were cultivated in 75 cm 2 tissue culture flasks (Greiner Bio-One) at 37 C and 5 % CO 2 .
Expression plasmids. The plasmid p88modDNhe, which encodes the full-length cDNA of the MuVi/1961.USA/0.88[H] strain (referred to as 88-1961 strain, GenBank accession no.: AF467767.2) and contains modifications in the UTRs, has been described previously (Sauder et al., 2011) . Plasmids expressing the 88-1961 N, P and L gene products (pTM1-88 N, pTM1-88 P and pTM1-88 L) have been described elsewhere (Malik et al., 2007b) . To enable the cloning of constructs in which the ORF of the HN protein of the 88-1961 strain was replaced by the corresponding ORF of the batMuV (GenBank accession no.: HQ660095.1), we altered the XhoI restriction site at nucleotide positions 6606-6611 by changing G6611 to A (p88modDNhe+Xho) by site-directed mutagenesis. To generate chimeric MuV genomes, we replaced the ORF of the F and/or HN protein of the 88-1961 strain by the corresponding ORFs of batMuV through direct cloning into the plasmid p88modDNhe+Xho (p88modDNhe +Xho_batF, p88modDNhe+Xho_batHN and p88modDNhe+Xho_batF +HN). The batMuV F and HN ORFs were flanked by the UTRs of the 88-1961 strain. Detailed descriptions of the generation of p88modDNhe +Xho and the chimeric plasmids, as well as primer sequences, are available upon request. All plasmids were verified by sequencing of the replaced ORFs and their flanked UTRs.
Rescue of recombinant viruses. BSR-T7/5 cells were grown in 25 cm 2 cell culture flasks (Greiner Bio-One) in DMEM supplemented with 5 % FCS until they reached 80-85 % confluency. At 30 min before transfection, the medium was replaced by 5 ml of fresh DMEM. Next, cells were transfected with 225 ng of pTM1-88 N, 37 ng of pTM1-88 P, 172 ng of pTM1-88 L and 6.95 µg of full-length MuV cDNA plasmids using ICAFectin transfection reagent (In-Cell-Art) according to the manufacturer¢s protocol. At 4 h post transfection (p.t.), the medium was removed and cells were maintained in 8 ml DMEM supplemented with 5 % FCS. At 48 h p.t., cells were transferred into two 75 cm 2 cell culture flasks and maintained in 15 ml DMEM with 5 % FCS. Supernatants were collected at day 8-12 p.t. -depending on the occurrence of syncytia or a widespread CPE -centrifuged at 2100 r.p.m. and 4 C for 10 min and finally stored at À80 C. In the following text, recombinant viruses are referred to as r88modDNhe, r88modDNhe+Xho, r88_batF, r88_batHN and r88_batF+HN. Virus rescue was performed in two independent trials, identified by the suffix 1 or 2. Unpurified viruses from each rescue were sequenced and subjected to further assays. The rescue of recombinant Jeryl Lynn virus (here termed rJL) from cDNA plasmid pMuV(MPBS) (kindly provided by Paul Duprex, Boston, MA), using helper plasmids pMuVNP, pMuVP and pMuVL (kindly provided by D. Clarke, Wyeth-Lederle Vaccines, Pearl River, NY), has been described before (Sauder et al., 2011) .
RNA extraction, reverse transcriptase PCR and nucleotide sequencing. Viral RNA was extracted from cell culture supernatants of infected Vero76 cells using the QIAamp MinElute Virus Spin Kit (QIA-GEN). Reverse transcriptase PCR was performed using random primers and SuperScriptII Reverse Transcriptase (both purchased from Life Technologies) according to the manufacturer¢s protocol. Specific primers were used to amplify 26 overlapping cDNA fragments with a length of 571 bp up to 862 bp. All PCRs were performed using Phusion HighFidelity DNA polymerase (Thermo Scientific). Finally, gel electrophoresis and extraction was performed using the QIAquick Gel Extraction Kit (QIAGEN). Sequencing of cDNA fragments was performed by a commercial service (Eurofins Genomics). Sequences of primers used for reverse transcriptase PCR and sequencing are available upon request.
Immunofluorescence microscopy. Cells were grown on coverslips and infected at an MOI of 0.05. At 1-5 days p.i., cells were fixed with PBS/3 % paraformaldehyde and permeabilized with 0.2 % Triton X-100. Viral proteins were detected by incubation with (i) polyclonal monospecific antibodies directed against the cytoplasmic tails (CT) of MuV F or HN (anti-F CT, anti-HN CT, both produced in the rabbit) (Krüger et al., 2015) or (ii) polyclonal rabbit sera containing neutralizing antibodies against MuV Kilham strain (Orvell et al., 1997) in a humidity chamber for 1 h. The incubation with ALEXA-Fluor 594-conjugated secondary antibodies directed against rabbits (Life Technologies) was performed in a humidity chamber for 30 min. Finally, the cells were incubated with DAPI (Roth) and mounted in Mowiol (Calbiochem) containing 2.5 % DABCO (1,4-diazabicyclo[2.2.2]octane; SigmaAldrich). Immunofluorescence analysis was performed using a Nikon Eclipse Ti microscope and NIS Elements AR software (Nikon).
Western blot analysis of purified viruses. To investigate the expression of MuV F and HN proteins in virions, we harvested virus containing supernatants of Vero76 cells at 5 days p.i. We loaded 1 ml of rMuV containing supernatant (diluted with DMEM to obtain a viral titre of 1Â10 6 p.f.u. ml
À1
) onto a 20 % sucrose cushion in PBS and centrifuged it at 17 000 g for 2 h at 4 C. After discarding the supernatant, we resuspended the virus pellet in 50 µl 2Â SDS-containing lysis buffer [50 mM Tris (pH 6.8), 10 % glycerol, 2 % SDS, 0.1 % bromophenol blue and 1 mM EDTA] and heated it for 15 min at 56 C, before the lysates of rMuV were loaded on an SDS gel and further subjected to SDS-PAGE and Western blotting. To perform SDS-PAGE under reducing conditions, we performed the incubation of samples for 15 min at 56 C in the presence of 0.1 M (final concentration) DTT. Following SDS-PAGE and blotting, MuV proteins were detected by incubation with antibodies directed against MuV N (anti-MuV N 696, mouse), MuV P (anti-MuV On: Mon, 17 Dec 2018 17:56:04 P 2037, mouse) (Orvell, 1984) or the CT of either MuV F or HN (anti-F/HN CT, rabbit), for 1 h at 4 C, and anti-rabbit or anti-mouse HRP (both purchased from Dako) for 45 min at 4 C. For the visualization of protein bands, membranes containing the immobilized proteins were incubated with Super Signal West Dura extended duration substrate (Thermo Scientific), placed in a ChemiDoc imager (Bio-Rad) and analysed with the Quanti One software (Bio-Rad). Quantification of Western blots was performed using ImageJ software (National Institutes of Health). To compare the amount of viral proteins incorporated into the different rMuVs generated, we normalized the protein contents of MuV P, F and HN to the content of MuV N. The relative protein contents of r88_batF, r88_batHN and r88_batF+HN were set in relation to r88modDNhe+Xho (set as 100 %). Mean values and SEM of three experiments have been calculated. In order to assess statistical significance, we performed two-tailed Student's t-tests.
In vitro growth kinetics. Cells were grown in 6-well plates until confluence and infected at an MOI of 0.05 in 800 µl DMEM for 1 h at 37 C on a rocking platform. The inoculum was removed and cells were washed with PBS for three times, before 2.5 ml of DMEM supplemented with 5 % FCS was added to the cells. Every 24 h, 250 µl of the supernatants was collected and stored at À80 C until all samples were collected. The removed supernatant was replaced by the same volume of fresh cell culture medium. Samples were collected from the time point 0 until 5 days p.i. To determine the virus titres, we performed a plaque assay in Vero76 cells. Accordingly, cells were grown in 12-well plates (Greiner Bio-One) and infected with 10-fold serial dilutions of virus containing supernatants for 1 h at 37 C on a rocking platform. After three washing steps with PBS, infected cells were overlaid with 1 % plaque agarose (Biozym) in Eagle's minimal essential medium without phenol red (Lonza) supplemented with 10 % FCS. At 4 days p.i. (r88_batF, r88_batF+HN) to 8 days p.i. (r88modDNhe, r88modDNhe+Xho, r88_batHN ), cells were fixed and stained by incubation with 0.1 % crystal violet (Merck) in formalin diluted in Aqua bidest. at room temperature overnight. Next, agarose was removed from the wells and cells were washed with Aqua bidest. Viral titres were determined by counting the number of plaques and multiplying this with the reciprocal of the dilution factor and the volume used for inoculation. Virus titres are given in p.f.u. per millilitre. Viral growth kinetics were performed in four independent trials for each construct. For evaluation, one-way repeated measured ANOVA and Tukey's multiple comparison test were performed.
In addition, cells were infected at an MOI of 0.05 and fixed with PBS/ 3 % paraformaldehyde at 0-5 days p.i. Cells were washed with PBS for three times and subsequently incubated with Giemsa staining solution (1 : 10 diluted with Aqua bidest.; Sigma-Aldrich) for 30 min. Next, cells were incubated with May Grünwald solution (Sigma-Aldrich) for 10 min. Finally, cells were washed with Aqua bidest., air-dried and analysed via light microscopy for the presence of syncytia and/or CPE. Microscopy was performed using a Nikon Eclipse Ti microscope and NIS Elements AR software (Nikon).
Neurovirulence. Neurovirulence testing was performed as described previously (Rubin et al., 2000) . Briefly, litters of newborn Lewis rats were inoculated intracranially (i.c.) within 16 h post-partum with 100 p.f.u. of virus in a volume of 20 µl using Eagle's minimal essential medium as virus diluent. One month post-inoculation, rats were humanely euthanized and brains were removed and fixed in 10 % neutral buffered formalin at 4 C for 3-5 days. Following sagittal division of brains and embedding in paraffin, one 10 µm section from each brain hemisphere at a distance of 1 mm from the anatomical midline was obtained and stained with haematoxylin and eosin. The cross-sectional areas of the entire brain section (excluding the cerebellum) and that of the lateral ventricle (enlarged following MuV infection) were measured using ImageJ software (National Institutes of Health). The ratio between these two measurements was calculated for both sections per rat and averaged to yield the rat neurovirulence score. The mean group neurovirulence score was determined for all rats inoculated with a given virus. Statistical analysis was carried out employing SigmaPlot11 software (Systat Software). All animal studies were conducted using protocols approved by the Food and Drug Administration's White Oak campus Institutional Animal Care and Use Committee in accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals.
Inhibition of infection by neutralizing antibodies. rMuV was incubated with polyclonal rabbit serum containing neutralizing antibodies directed against MuV SBL or Kilham strain (Orvell et al., 1997) (1 : 50 diluted in cell culture medium) for 1 h at 37 C. Pre-incubated viruses were added to Vero76 cells grown in 24-well plates and incubated for 1 h at 37 C on a rocking platform. Cells were washed with PBS three times and incubated in fresh cell culture medium. Supernatants of infected cells were collected at 3 days p.i. and subjected to plaque assay to determine the viral titre. As a control for the specificity of antibodies and to exclude an unspecific effect of the rabbit sera on viral replication, we pre-incubated recombinant VSV, which codes for an EGFP, in an additional ORF between the VSV G and VSV L genes (VSV-EGFP) (Hoffmann et al., 2010) with neutralizing anti-MuV antibodies and subjected it to plaque assay. At 1 day p.i., green fluorescing foci were counted to determine the virus titre for VSV-EGFP. This assay was performed in three independent trials. For evaluation, the relative infectivity was calculated by comparison of the viral titres obtained following pre-incubation with neutralizing antibodies to the titre obtained for untreated viruses, which was set as 100 %. The mean value and standard error of means were calculated from the results obtained for all three trials.
Inhibition of viral neuraminidase activity. To analyse whether group IV anti-mumps antibodies (Orvell, 1984) have an inhibitory effect on the neuraminidase activity of batMuV HN, we pre-incubated viruses with 10 µl of antibody 2024 or 5342 for 1 h at 37 C in black 96-well plates. Influenza virus of the subtype H3N2 (A/sw/Herford/IDT5932/ 2007, obtained from IDT Biologika) served as a control to prove the specificity of the selective inhibition of MuV neuraminidase activity. After incubation of viruses and antibodies, 0.3 mM 2¢-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (4-MUNANA; Sigma-Aldrich) was added and the emission was measured by a GENios pro chemiluminometer (Tecan) using an excitation wavelength of 355 nm and an emission wavelength of 460 nm at 1 h post-incubation. The assay was performed three times, with each value determined in triplicate. Mean value and standard deviation have been calculated for each trial. For evaluation, the relative neuraminidase activity has been calculated by normalizing the emission of pre-incubated viruses to the emission obtained for the untreated viruses.
